Lianhua Qingwen prescription for Coronavirus disease 2019 (COVID-19) treatment: Advances and prospects

Autor: Jie Chen, Hong-Mei Fang, Lian-Di Kan, Qin Chen, Liu-Cheng Li, Hua-Qian Jin, Ye-Cheng Jin, Jiao Qu, Wencheng Zhou, Zhi-Hui Zhang
Jazyk: angličtina
Rok vydání: 2020
Předmět:
0301 basic medicine
ALI
acute lung injury
IBV
influenza B virus
medicine.disease_cause
law.invention
0302 clinical medicine
Randomized controlled trial
law
SARS
Severe Acute Respiratory Syndrome
Medicine
Chinese Traditional
Antiviral activity
Lung
IP
interferon-inducible protein
NF-κB
nuclear factor-kappa B
Coronavirus
Research data
ADRs
adverse drug reactions
General Medicine
AECOPD
acute exacerbation of chronic obstructive pulmonary disease
Treatment Outcome
HPLC
high performance liquid chromatography
030220 oncology & carcinogenesis
UPLC-DAD-QTOF-MS
ultraperformance liquid chromatography coupled with diode-array detector and quadrupole time-of-flight mass spectrometry
LPS
lipopolysaccharide
AGE
advanced glycation end products
TCM
traditional Chinese medicine
MIP
macrophage inflammatory protein
medicine.medical_specialty
RAGE
receptor of advanced glycation end products
Coronavirus disease 2019 (COVID-19)
Complementary strategy
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
RM1-950
ACE2
angiotensin-converting enzyme 2
Antiviral Agents
Article
EC50
median effective concentrations
03 medical and health sciences
medicine
Humans
Effective treatment
COVID-19
Coronavirus Disease 19
IFN
interferon
Medical prescription
Intensive care medicine
ComputingMethodologies_COMPUTERGRAPHICS
Pharmacology
Lung protection
business.industry
SARS-CoV-2
Lianhua Qingwen
MCP
monocyte chemoattractant protein
COVID-19 Drug Treatment
IL
interleukin
030104 developmental biology
SARS-CoV-2
Severe Acute Respiratory Syndrome Coronavirus 2
COPD
chronic obstructive pulmonary disease
Therapeutics. Pharmacology
business
LHQW
Lianhua Qingwen
Drugs
Chinese Herbal
Zdroj: Biomedicine & Pharmacotherapy
Biomedicine & Pharmacotherapy, Vol 130, Iss, Pp 110641-(2020)
ISSN: 1950-6007
0753-3322
Popis: Graphical abstract
Highlights • COVID-19 has led to serious death and lacks treatment strategies. • Lianhua Qingwen is a commonly used Chinese patent medicine to treat viral infection. • Lianhua Qingwen has antiviral, anti-inflammatory and immunoregulatory activities. • Lianhua Qingwen combined with conventional treatment obviously improved COVID-19. • Lianhua Qingwen can be a complementary strategy for treating COVID-19.
Background An outbreak of Coronavirus Disease 2019 (COVID-19) which was infected by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is still spreading and has led to unprecedented health emergency over the world. Though no specific drug has been developed so far, emerging agents have been confirmed effective or potentially beneficial to restrain it. Lianhua Qingwen (LHQW) is a commonly used Chinese medical preparation to treat viral influenza, including in the fight against SARS in 2002–2003 in China. Recent data also showed that LHQW played a vigorous role in COVID-19 treatment. Purpose This review will elucidate the pre-clinical and clinical evidence of LHQW in lung protection and antiviral activities, and provide timely data delivery for the exploration of effective treatment strategies in the therapy of COVID-19. Study design and method The research data were obtained from the academic databases (up to August 8, 2020) including Pubmed, CNKI and Web of Science, on ethnobotany and ethno medicines. The search keywords for screening the literature information were “virus”, “COVID-19”, or “SARS-CoV-2”, and “Lianhua Qingwen”. The documents were filtered and summarized for final evaluation. Results The collected evidence demonstrated that LHQW exhibited benefits against COVID-19. Impressively, LHQW in conjunction with conventional treatment could significantly improve COVID-19 patients as a synergetic strategy. The mechanisms were mainly involved the antiviral activity, and regulation of inflammation response as well as immune function. Conclusion Although the data were far from adequate, the latest advances had shown the benefits of LHQW in COVID-19, especially in combination with other antiviral drugs. This review provides comprehensive evidence of LHQW as a complementary strategy for treating COVID-19. Nevertheless, imperious researches should be conducted to clarify the unconfirmed effects, regulatory mechanisms and adverse reactions of LHQW in treating COVID-19 by means of well designed randomized controlled trials.
Databáze: OpenAIRE
Externí odkaz: